Last reviewed · How we verify

Carlos A Acosta-Olivo — Portfolio Competitive Intelligence Brief

Carlos A Acosta-Olivo pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Tranexamic acid tablets Tranexamic acid tablets phase 3 Antifibrinolytic agent Plasminogen / Plasmin Hematology / Hemostasis

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Chinese Academy of Medical Sciences, Fuwai Hospital · 1 shared drug class
  2. Dr. Lutfi Kirdar Kartal Training and Research Hospital · 1 shared drug class
  3. Hamilton Health Sciences Corporation · 1 shared drug class
  4. Henry Ford Health System · 1 shared drug class
  5. Massachusetts General Hospital · 1 shared drug class
  6. Montefiore Medical Center · 1 shared drug class
  7. Mount Sinai Hospital, Canada · 1 shared drug class
  8. Aswan University Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Carlos A Acosta-Olivo:

Cite this brief

Drug Landscape (2026). Carlos A Acosta-Olivo — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/carlos-a-acosta-olivo. Accessed 2026-05-17.

Related